Add Yahoo as a preferred source to see more of our stories on Google. Myelofibrosis is a rare blood cancer causing bone marrow scarring Opna Bio has received the US Food and Drug Administration’s (FDA ...

January 21, 2026-- Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology th ...

In the draft guidance, the agency discusses how sponsors can leverage MRD and complete response rates as near-term efficacy measures and speed new therapies to market.

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...

Patients with rare blood disorders are speaking out about their lifelong experiences, to mark the launch of a new study led by the University of Leeds.

The presentation will serve as an encore of data reported previously, highlighting results from Exicure’s open-label, multicenter Phase 2 trial (NCT05561751) evaluating burixafor in patients with ...

Receiving a diagnosis of Chronic Myeloid Leukemia (CML) can be frightening, but it is important to understand that the management of this disease is one of the greatest success stories in modern ...

One‑year‑old Charlotte Akers’ life hung in the balance until her one‑in‑a‑billion match was found — a stranger from Poland ...

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF ...

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...